Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Niaspan Stories

2014-03-21 12:24:25

MUMBAI, India and BALTIMORE, March 21, 2014 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Niacin Extended-Release Tablets USP, 500 mg, 750 mg, 1000 mg strengths having received final approval from the United States Food and Drug Administration (FDA) yesterday. Lupin's Niacin Extended-Release Tablets USP, 500 mg, 750 mg, 1000 mg strengths are the AB-rated generic...

2013-03-25 16:25:03

OXFORD, England, March 25, 2013 /PRNewswire/ -- Senior researchers at Oxford University's Clinical Trial Service Unit welcomed today's statement by the Principal Investigators of the AIM-HIGH trial about the consistency of the adverse effects seen in the AIM-HIGH trial of extended-release niacin (Niaspan) with those reported from the HPS2-THRIVE trial of extended-release niacin given in combination with laropiprant (Tredaptive). The findings of the HPS2-THRIVE trial of...

2012-03-19 02:25:25

PARSIPPANY, N.J., March 19, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Niacin Extended-release Tablets, 500 mg and 1000 mg. Watson's ANDA products are generic versions of Abbott Laboratories' NIASPAN®. Abbott Laboratories and Abbott Respiratory LLC filed suit against...

2011-11-15 07:18:00

ORLANDO, Fla., Nov. 15, 2011 /PRNewswire/ -- Final results were presented today from the AIM-HIGH study, a National Heart, Lung and Blood Institute (NHLBI) study. The study was designed to test whether raising HDL "good" cholesterol by adding Niaspan to simvastatin would provide an additional 25 percent reduction in cardiovascular outcomes in patients with established cardiovascular disease and well-controlled LDL "bad" cholesterol levels. The study was stopped early following an interim...

2011-05-26 10:01:00

ABBOTT PARK, Ill., May 26, 2011 /PRNewswire/ -- The National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), today disclosed results from an interim analysis of the AIM-HIGH clinical trial. AIM-HIGH was designed to test whether raising HDL and lowering triglycerides in a patient population with established cardiovascular disease and very well controlled LDL levels could produce an additional 25 percent benefit on cardiovascular outcomes. The...

2009-11-15 17:28:00

ORLANDO, Fla., Nov. 15 /PRNewswire-FirstCall/ -- Results from the investigator-initiated ARBITER 6 - HALTS study showed patients at high cardiovascular risk had significant regression of atherosclerosis after 8 and 14 months of therapy with Abbott's Niaspan® (niacin extended-release tablets) plus a statin, the study's primary endpoint. In a pre-specified secondary endpoint of the study, treatment with Niaspan plus statin also resulted in significantly fewer major adverse...

2008-08-11 09:01:40

Cortria Corporation today announced the appointment of Gene Cefali, Pharm.D, Ph.D., as Senior Vice President of Clinical Pharmacology and Formulation Development. Dr. Cefali was previously Vice President of Lead Optimization at Kos Pharmaceuticals (acquired by Abbott Laboratories), where he played a major role in the development of Niaspan(R), a novel formulation of niacin and widely prescribed anti-dyslipidemic medicine, as well as three Niaspan(R) line-extension products. Dr. Cefali is a...

2005-11-15 12:01:56

By Ransdell Pierson and Bill Berkrot DALLAS (Reuters) - Plaque shrank in the neck arteries of heart patients taking Kos Pharmaceuticals Inc.'s drug Niaspan along with a statin cholesterol drug, researchers said on Tuesday, suggesting such drug combinations may be able to dramatically lower the incidence of heart disease. Niaspan, Kos' biggest-selling drug, is used to raise levels of heart-protective HDL cholesterol. Statins, the most widely used heart drugs such as Pfizer Inc.'s...